A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma.

@article{Yeo2009API,
  title={A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma.},
  author={Winnie Yeo and Boon-cher Goh and Christophe Le Tourneau and Stephanie Ruth Green and Judy H. Chiao and Lillian L Siu},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={6026}
}
6026 Background: Seliciclib is a selective inhibitor of cyclin dependent kinases (CDKs) 2, 7 and 9. In a phase I study of 2 weeks of oral administration, clinical antitumor activity was observed in patients with treatment-naive nasopharyngeal carcinoma (NPC) and biological effects consistent with CDK inhibition were detected in tumor biopsy samples. We are conducting a multicenter, randomized phase 2 study to evaluate the safety and efficacy of prolonged administration of seliciclib in patients… CONTINUE READING

Similar Papers

Loading similar papers…